首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Erratum: Bariatric surgery and medicines [Correction]. 更正:减肥手术和药物[更正]。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.074

[This corrects the article on p. 162 in vol. 45, PMID: 36382169.].

[这更正了第45卷第162页的文章，PMID: 36382169]。
{"title":"Erratum: Bariatric surgery and medicines [Correction].","authors":"","doi":"10.18773/austprescr.2022.074","DOIUrl":"https://doi.org/10.18773/austprescr.2022.074","url":null,"abstract":"<p><p>[This corrects the article on p. 162 in vol. 45, PMID: 36382169.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/65/austprescr-45-219.PMC9722356.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mecasermin for primary insulin-like growth factor-1 deficiency. Mecasermin治疗原发性胰岛素样生长因子-1缺乏。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.077
{"title":"Mecasermin for primary insulin-like growth factor-1 deficiency.","authors":"","doi":"10.18773/austprescr.2022.077","DOIUrl":"https://doi.org/10.18773/austprescr.2022.077","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/a7/austprescr-45-215.PMC9722352.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wither Australian Prescriber? 枯萎澳大利亚处方?
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.076
John Dowden
{"title":"Wither <i>Australian Prescriber</i>?","authors":"John Dowden","doi":"10.18773/austprescr.2022.076","DOIUrl":"https://doi.org/10.18773/austprescr.2022.076","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/2e/austprescr-45-210.PMC9722344.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pemigatinib for cholangiocarcinoma. Pemigatinib治疗胆管癌。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.078
{"title":"Pemigatinib for cholangiocarcinoma.","authors":"","doi":"10.18773/austprescr.2022.078","DOIUrl":"https://doi.org/10.18773/austprescr.2022.078","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/b6/austprescr-45-216.PMC9722347.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selinexor for multiple myeloma. Selinexor治疗多发性骨髓瘤。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.072
Exportin-1 is an essential nuclear exporter of many tumour suppressor proteins, growth regulator proteins and several classes of messenger RNAs, including those of oncogenic proteins. It is overexpressed in several cancers including multiple myeloma. Selinexor is a selective inhibitor of exportin-1. This inhibition leads to marked accumulation of the tumour suppressor proteins and growth regulator proteins in the nucleus and reduced expression of several oncoproteins, resulting in cell cycle arrest and apoptosis of cancer cells.
{"title":"Selinexor for multiple myeloma.","authors":"","doi":"10.18773/austprescr.2022.072","DOIUrl":"https://doi.org/10.18773/austprescr.2022.072","url":null,"abstract":"Exportin-1 is an essential nuclear exporter of many tumour suppressor proteins, growth regulator proteins and several classes of messenger RNAs, including those of oncogenic proteins. It is overexpressed in several cancers including multiple myeloma. Selinexor is a selective inhibitor of exportin-1. This inhibition leads to marked accumulation of the tumour suppressor proteins and growth regulator proteins in the nucleus and reduced expression of several oncoproteins, resulting in cell cycle arrest and apoptosis of cancer cells.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/39/austprescr-45-217.PMC9722349.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes. 地西他滨/cedazuridine治疗慢性髓单核细胞白血病，骨髓增生异常综合征。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.071
{"title":"Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes.","authors":"","doi":"10.18773/austprescr.2022.071","DOIUrl":"https://doi.org/10.18773/austprescr.2022.071","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/b8/austprescr-45-213.PMC9722354.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elasomeran/imelasomeran for prevention of COVID-19. 用于预防新冠肺炎的Elasomeran/imelasomeran。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.073
{"title":"Elasomeran/imelasomeran for prevention of COVID-19.","authors":"","doi":"10.18773/austprescr.2022.073","DOIUrl":"https://doi.org/10.18773/austprescr.2022.073","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/af/austprescr-45-214.PMC9722357.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteonecrosis of the jaw and denosumab. 颌骨骨坏死和地诺单抗。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.066
Alastair N Goss
{"title":"Osteonecrosis of the jaw and denosumab.","authors":"Alastair N Goss","doi":"10.18773/austprescr.2022.066","DOIUrl":"https://doi.org/10.18773/austprescr.2022.066","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/3e/austprescr-45-208.PMC9722355.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10433277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The end of NPS MedicineWise. NPS MedicineWise的终结。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.075
Deborah Rigby
{"title":"The end of NPS MedicineWise.","authors":"Deborah Rigby","doi":"10.18773/austprescr.2022.075","DOIUrl":"https://doi.org/10.18773/austprescr.2022.075","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/25/austprescr-45-186.PMC9722346.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diuretics in the management of chronic heart failure: when and how. 利尿剂在慢性心力衰竭治疗中的应用:时间和方式。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.069
Joseph S Magdy, James McVeigh, Praveen Indraratna

Heart failure is an increasingly prevalent condition resulting in recurrent hospitalisations and significant mortality and morbidity. The management of heart failure has evolved, and multiple drugs have an established mortality benefit in heart failure with reduced ejection fraction. Although the focus should be on ensuring that patients are treated with the maximum tolerated doses of these guideline-directed therapies, diuretics continue to play a key role in the management of clinical congestion in all forms of heart failure. Clinicians play a key role in heart failure management. Familiarity with the role of diuretics and their dosing and monitoring is critical.

心力衰竭是一种越来越普遍的疾病，导致反复住院和显著的死亡率和发病率。心力衰竭的治疗已经发生了变化，多种药物在降低射血分数的心力衰竭中具有确定的死亡率益处。尽管重点应放在确保患者接受指南指导的最大耐受剂量的治疗上，但利尿剂在各种形式心力衰竭的临床充血管理中仍然发挥着关键作用。临床医生在心力衰竭管理中起着关键作用。熟悉利尿剂的作用及其剂量和监测至关重要。
{"title":"Diuretics in the management of chronic heart failure: when and how.","authors":"Joseph S Magdy,&nbsp;James McVeigh,&nbsp;Praveen Indraratna","doi":"10.18773/austprescr.2022.069","DOIUrl":"https://doi.org/10.18773/austprescr.2022.069","url":null,"abstract":"<p><p>Heart failure is an increasingly prevalent condition resulting in recurrent hospitalisations and significant mortality and morbidity. The management of heart failure has evolved, and multiple drugs have an established mortality benefit in heart failure with reduced ejection fraction. Although the focus should be on ensuring that patients are treated with the maximum tolerated doses of these guideline-directed therapies, diuretics continue to play a key role in the management of clinical congestion in all forms of heart failure. Clinicians play a key role in heart failure management. Familiarity with the role of diuretics and their dosing and monitoring is critical.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/1e/austprescr-45-200.PMC9722345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1